NEWS

Bioquark Hopes to Bring Dead Back to Life Using Stem Cell Therapy – India West

India WestBioquark Hopes to Bring Dead Back to Life Using Stem Cell TherapyIndia WestA Philadelphia-based company along with an Indian orthopedic surgeon has said it will start a new type of stem cell therapy that claims it can bring people back from t… Continue reading

New CAR T-cell Therapy Seen to Induce Lasting Remission in Advanced Multiple Myeloma Patients – Myeloma Research News

New CAR T-cell Therapy Seen to Induce Lasting Remission in Advanced Multiple Myeloma PatientsMyeloma Research NewsAn ongoing Phase 1 trial testing a novel CAR T-cell therapy has shown promising results in relapsed or treatment-resistant (refractory) mu… Continue reading

Outcomes of Primary Total Knee Arthroplasty in Patients With Hematopoietic Stem Cell Transplantation – Healio

HealioOutcomes of Primary Total Knee Arthroplasty in Patients With Hematopoietic Stem Cell TransplantationHealioPatients who have undergone hematopoietic stem cell transplantation to treat underlying bone marrow pathology represent a unique and potenti… Continue reading

Researchers find long-lasting benefits of gene therapy in dog model of myotubular myopathy – News-Medical.net

News-Medical.net

Researchers find long-lasting benefits of gene therapy in dog model of myotubular myopathy News-Medical.net Researchers who previously showed that a gene therapy treatment could save the lives of dogs with a deadly disease called myotubular myopathy—a type of muscular dystrophy that affects the skeletal muscles—have found that the therapy is long-lasting.

FierceBiotech

As Novartis preps for first CAR–T FDA AdComm, Juliet data revealed FierceBiotech The FDA ‘breakthrough’ tagged Juliet data, which many have been waiting for to see how well it could stack up against rival Kite Pharma, was assessing CTL019 (a.k.a tisagenlecleucel) in 51 relapsing/remitting diffuse large B-cell lymphoma (r/r DLBCL) … Novartis touts new T–cell therapy data in race for FDA approvalReuters Novartis’ CAR–T stacks up to Kite in lymphomaBioPharma Dive Novartis’ posts landmark CAR–T data as head-to-head rivalry with Kite Pharma loomsEndpoints News GlobeNewswire (press release) all 8 news articles »

FierceBiotech

As Novartis preps for first CAR–T FDA AdComm, Juliet data revealed FierceBiotech It’s been a big week for CAR–T: Novartis, Juno, Kite, Bluebird Bio and Nanjing Legend Biotech all posted positive data for the cutting-edge experimental cancer class at ASCO, and now Novartis has revealed the long-awaited interim Juliet data for its … Novartis touts new T–cell therapy data in race for FDA approvalReuters Novartis’ CAR–T stacks up to Kite in lymphomaBioPharma Dive Novartis interim results from global, pivotal CTL019 trial show durable complete responses in adults with r/r DLBCLGlobeNewswire (press release) all 8 news articles »

Reuters

Novartis touts new T–cell therapy data in race for FDA approval Reuters Globally, there are some 183 CAR–T trials underway. In March, Novartis filed CTL019 with the U.S. Food and Drug Administration for fast-track approval in B-cell acute lymphoblastic leukemia (ALL) in young patients. The FDA has scheduled a July 12 … As Novartis preps for first CAR–T FDA AdComm, Juliet data revealedFierceBiotech Novartis posts landmark CAR–T data as head-to-head rivalry with Kite Pharma loomsEndpoints News Novartis’ CAR–T stacks up to Kite in lymphomaBioPharma Dive GlobeNewswire (press release) all 9 news articles »